"The ability to specifically identify the 027 strain will enable tracking of local hospital outbreaks of this strain, which is likely to be of significant value to infection control professionals in curbing the spread of C. difficile," said Dr. David Persing, Cepheid's Executive Vice President, Chief Medical & Technology Officer. "Xpert C. difficile comprises the attributes of high accuracy and rapid, on-demand results that are of the greatest importance in controlling transmission of this emerging pathogen."
CDAD has become more common and is increasing in severity, with an attributable mortality of 6-15 percent. C. difficile is acquired via contact with infected patients or from exposure to contaminated hospital environments. C. difficile disease can range in severity from mild to sever diarrhea, pseudomembranous colitis, sepsis, and death. If C. difficile infection is detected early, studies show reduced length of stay, improved patient outcomes, and significant cost savings for hospitals.
About the GeneXpert(R) System Molecular Diagnostic Platform
The GeneXpert(R) System is a closed, self-contained, fully-integrated
and automated platform that represents a paradigm shift in the automation
of molecular analysis, producing accurate results in a timely manner with
minimal risk of contamination. The GeneXpert System is the only system to
combine on- board sample preparation with real-time PCR (polymerase chain
reaction) amplification and detection functions for fully integrated and
automated nucleic acid analysis. The system is designed to purify,
concentrate, detect and identify targeted nucleic acid sequences there
Copyright©2008 PR Newswire.
All rights reserved